Cargando…

Viscoelastic tests in liver disease: where do we stand now?

Hemostasis is a complex physiological process based on the balance between pro-coagulant and anticoagulant systems to avoid pathological bleeding or thrombosis. The changes in standard coagulation tests in liver disease were assumed to reflect an acquired bleeding disorder, and cirrhotic patients we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buliarca, Alina, Horhat, Adelina, Mocan, Tudor, Craciun, Rares, Procopet, Bogdan, Sparchez, Zeno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218367/ https://www.ncbi.nlm.nih.gov/pubmed/34163112 http://dx.doi.org/10.3748/wjg.v27.i23.3290

Ejemplares similares

Pulmonary complications of portal hypertension: The overlooked decompensation
por: Craciun, Rares, et al.
Publicado: (2022)

Endoscopic or percutaneous biliary drainage in hilar cholangiocarcinoma: When and how?
por: Mocan, Tudor, et al.
Publicado: (2021)

Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma: Fall Forward or Move Forward?
por: Sparchez, Zeno, et al.
Publicado: (2021)

Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?
por: Sparchez, Zeno, et al.
Publicado: (2021)

Hepatic Hydrothorax—An Independent Decompensating Event Associated with Long-Term Mortality in Patients with Cirrhosis
por: Matei, Daniela, et al.
Publicado: (2021)

Contrast enhancement for ultrasound-guided interventions: when to use it and what to expect?
por: Sparchez, Zeno, et al.
Publicado: (2022)

Refining Liver Biopsy in Hepatocellular Carcinoma: An In-Depth Exploration of Shifting Diagnostic and Therapeutic Applications
por: Spârchez, Zeno, et al.
Publicado: (2023)

Liver transplantation for hepatocellular carcinoma: Where do we stand?
por: Santopaolo, Francesco, et al.
Publicado: (2019)

Angiogenesis inhibitors in clinical development; where are we now and where are we going?
por: Eskens, F A L M
Publicado: (2004)

Hepatitis C virus micro-elimination: Where do we stand?
por: Mangia, Alessandra, et al.
Publicado: (2021)

Novel approaches in search for biomarkers of cholangiocarcinoma
por: Mocan, Lavinia-Patricia, et al.
Publicado: (2022)

Role of endoscopic ultrasound in liver disease: Where do we stand in 2017?
por: Saraireh, Hamzeh A, et al.
Publicado: (2017)

Role of endoscopic ultrasound in vascular interventions: Where are we now?
por: Fugazza, Alessandro, et al.
Publicado: (2022)

Screening and surveillance methods for dysplasia in inflammatory bowel disease patients: Where do we stand?
por: Galanopoulos, Michail, et al.
Publicado: (2018)

Noninvasive markers of liver steatosis and fibrosis after liver transplantation – Where do we stand?
por: Mikolasevic, Ivana, et al.
Publicado: (2021)

Biliary atresia: Where do we stand now?
por: Govindarajan, Krishna Kumar
Publicado: (2016)

Mechanical Thrombectomy- Where Do We Stand Now ?
por: Chakraborty, Debabrata, et al.
Publicado: (2022)

Clinical chorioamnionitis: where do we stand now?
por: Lukanović, David, et al.
Publicado: (2023)

Esophagogastric junction outflow obstruction: Where are we now in diagnosis and management?
por: Samo, Salih, et al.
Publicado: (2019)

Second-line rescue treatment of Helicobacter pylori infection: Where are we now?
por: Lin, Te-Fu, et al.
Publicado: (2018)

Circulating tumor DNA: Where are we now? A mini review of the literature
por: Galarza Fortuna, Gliceida Maria, et al.
Publicado: (2020)

Calculus detection technologies: where do we stand now?
por: Archana, V
Publicado: (2014)

Open Bankart Repair: Where do We Stand Now?
por: Kholinne, Erica, et al.
Publicado: (2019)

The genetic patterns of bladder cancer. Where do we stand now?
por: Salagierski, Maciej
Publicado: (2013)

The Battle Against COVID-19: Where Do We Stand Now?
por: Negahdaripour, Manica
Publicado: (2020)

Monkeypox virus crosstalk with HIV; where do we stand now?
por: Shafaati, Maryam, et al.
Publicado: (2022)

Antiglutamatergic agents for obsessive-compulsive disorder: Where are we now and what are possible future prospects?
por: Maraone, Annalisa, et al.
Publicado: (2021)

The Advance Directives and Foregoing of Life Support: Where do we Stand Now?
por: Mani, Raj Kumar, et al.
Publicado: (2018)

Tailoring treatment for MALT lymphoma patients: where do we stand now?
por: Johnson, Peter W., et al.
Publicado: (2017)

Cutaneous and Mucosal Melanomas of Uncommon Sites: Where Do We Stand Now?
por: Dika, Emi, et al.
Publicado: (2021)

Active surveillance in prostate cancer management: where do we stand now?
por: Dragan, Jędrzej, et al.
Publicado: (2020)

Defining the Pseudomonas Genus: Where Do We Draw the Line with Azotobacter?
por: Özen, Asli I., et al.
Publicado: (2011)

Pembrolizumab in endometrial cancer: Where we stand now
por: Aravantinou-Fatorou, Aikaterini, et al.
Publicado: (2021)

Apical polarity in three-dimensional culture systems: where to now?
por: Inman, Jamie L, et al.
Publicado: (2010)

Strengthening scientific credibility against misinformation and disinformation: Where do we stand now?
por: Jeng, Wei, et al.
Publicado: (2022)

The Role of Immunohistochemistry in the Differential Diagnosis between Intrahepatic Cholangiocarcinoma, Hepatocellular Carcinoma and Liver Metastasis, as Well as Its Prognostic Value
por: Mocan, Lavinia Patricia, et al.
Publicado: (2023)

Where Do We Stand?
Publicado: (1891)

Contemporary role of liver biopsy in hepatocellular carcinoma
por: Sparchez, Zeno, et al.
Publicado: (2018)

Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update
por: Turkay, Cansel, et al.
Publicado: (2010)

ArthroplastyWatch.com three-year follow-up: where do we stand now?
por: Alriksson-Schmidt, Ann, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lpmv1mom0bjb00dagg4rq46v84